RBC Capital Defending Sarepta Therapeutics (SRPT), 'we believe weakness presents a buying opportunity'

Raymond James Stays Sidelined on Sarepta (SRPT) Citing 'heavily eclipsed market opportunity' and 'binary risk heading into EMBARK'

Raymond James analyst Danielle Brill reiterated a Market Perform rating and {REMOVEPT} price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "

oday, Sarepta announced that the FDA has pushed back the PDUFA date for SRP-9001 to June 22 (was May 29). The reason for the delay was reportedly to provide more time to complete the regulatory review, labeling discussions,... More

William Blair Defends Sarepta Therapeutics (SRPT)

William Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "We believe that SRP-9001 represents both a meaningful therapy for patients and a significant opportunity for Sarepta. Competing programs have faced safety concerns that have led to the halting of trials,... More

Citi on Sarepta Therapeutics (SRPT): 'We expect shares to trade towards the $120s today', 'Buy on weakness'

Citi analyst Neena Bitritto-Garg reiterated a Buy rating and $204.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "This mornings announcement of a PDUFA delay (decision expected by June 22) is a surprise to us given FDAs commitment to sticking to... More

Sarepta (SRPT) tumbles 15% on 9001 decision delay; Analyst sees a buying opportunity

(Updated - May 24, 2023 8:50 AM EDT)

Sarepta Therapeutics (NASDAQ: SRPT) shares fell as much as 14.8% in early Wednesday trading after the medical research company said the U.S. Food and Drug Administration (FDA) informed the company it requires modest additional time to... More

Sarepta Therapeutics (SRPT) Falls 9% After Saying FDA Needs Additional Time to Complete Review of SRP-9001

(Updated - May 24, 2023 8:10 AM EDT)

Sarepta Therapeutics (NASDAQ: SRPT) Falls 9% After Saying FDA Needs Additional... More

Sarepta Therapeutics (SRPT) reports FDA requires additional time to complete review of SRP-9001

(Updated - May 24, 2023 8:09 AM EDT)

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

BofA on Sarepta's (SRPT) 9001: All signs point to approval, but we think 3-month extension could occur

BofA analyst Tazeen Ahmad: "Ahead of the highly anticipated May 29th PDUFA for SRP-9001 in DMD, we reiterate our strong conviction on approvability, supported by a positive adcom result. We view recent comments from Peter Marks during the adcom and ASGCT as supportive of the approval and indicative of... More